Quote:
Originally Posted by Indian Chief
J&J expects to have phase 3 data available at the end of January. If it all looks good, you're talking emergency approval in February.
Keep fingers crossed on that one because it offers significant advantages over Pfizer and Moderna.
|
What are the advantages? My big buying criteria are efficacy and to a much lesser degree side effects. The one dose thing doesn't really make me much difference, nor does storage. Is there anything else I should be considering?